Seasonal influenza vaccination in Kenya: an economic evaluation using dynamic transmission modelling

Table 6 Incremental net monetary benefit values and probabilities for each vaccination strategy at a willingness-to-pay threshold of $872 per DALY averted

Strategy	Mean INMB value in ‘000 s	INMB 95% credible interval in ‘000 s		Probability of highest INMB benefit	Rank
Strategy	Mean INMB value in ‘000 s	Lower quantile	Upper quantile	Probability of highest INMB benefit	Rank
Strategy IA	− 472	− 6201	10,054	4%	5
Strategy IB	3	− 5975	13,302	3%	1
Strategy IC	− 217	− 6976	13,545	0%	3
Strategy ID	− 3424	−10,351	9188	0%	8
Strategy IIA	− 1293	−14,377	23,996	11%	7
Strategy IIB	− 581	−13,854	28,726	7%	6
Strategy IIC	− 387	−15,597	31,947	2%	4
Strategy IID	− 7507	−22,440	20,834	0%	11
Strategy IIIA	− 7077	−36,674	53,262	12%	10
Strategy IIIB	− 7531	−35,320	44,647	12%	12
Strategy IIIC	− 3633	−39,244	70,255	14%	9
Strategy IIID	− 20,326	−54,467	42,876	0%	13
No vaccine	0	–	–	35%	2

INMB incremental net monetary benefit. Strategies are vaccinating children 6–23 months (strategy I), 2–5 years (strategy II) and 6–14 years (strategy III) with either the Southern Hemisphere influenza vaccine (Strategy A) or Northern Hemisphere vaccine (Strategy B) or both (Strategy C: twice yearly 3-month vaccination periods, or Strategy D: year-round vaccination)

ISSN: 1741-7015